Expression Profiling Stratifies Mesothelioma Tumors and Signifies Deregulation of Spindle Checkpoint Pathway and Microtubule Network with Therapeutic Implications

1. International Agency for Research on Cancer, World Health Organization. Estimatedcancer Incidence, Mortality, Prevalence and Disability-adjusted life years (DALYs)Worldwide in2008. http://globocan.iarc.fr/(17August2013,datelastaccessed).2. Vital Statistics Japan (Ministry of Health, Labour and Welfare). http://ganjoho.jp/professional/statistics/statistics.html (17 August 2013, date last accessed).3. Son T, Hyung WJ, Lee JH et al. Clinical implication of an insufficient number ofexamined lymph nodes after curative resection for gastric cancer. Cancer 2012;118: 4687–4693.4. Edge SB BD, Compton CC, Fritz AG et al. AJCC Cancer Staging Manual, 7th ed.NewYork: Springer2010.5. Zu H, Wang F, Ma Y et al. Stage-stratified analysis of prognostic significance oftumor size inpatients withgastric cancer.PLoS One2013; 8(1):e545026. Kunisaki C, Makino H, Kimura J et al. Impact of lymphovascular invasion inpatients withstage I gastric cancer.Surgery 2010; 147:204–211.7. Li C, Oh SJ, Kim S et al. Macroscopic Borrmann type as a simple prognostic indicatorinpatientswithadvancedgastriccancer.Oncology2009; 77: 197 –204.8. Kunisaki C, Akiyama H, Nomura M et al. Clinicopathologic characteristics and surgicaloutcomesof mucinousgastriccarcinoma. Ann SurgOncol 2006; 13: 836 –842.9. Talamonti MS, Kim SP, Yao KA et al. Surgical outcomes of patients with gastriccarcinoma: the importance of primary tumor location and microvessel invasion.Surgery 2003; 134:720–727;discussion 727–9.10. Iasonos A, Schrag D, Raj GV et al. How to build and interpret a nomogram forcancer prognosis. JClin Oncol2008; 26: 1364–1370.11. Han DS, Suh YS, Kong SH et al. Nomogram predicting long-term survival after d2gastrectomyfor gastric cancer. JClin Oncol2012; 30: 3834–3840.12. Kattan MW, Karpeh MS, Mazumdar M et al. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003;21:3647–3650.13. Kim JH, Kim HS, Seo WY et al. External validation of nomogram for the predictionof recurrence after curative resection in early gastric cancer. Ann Oncol 2012; 23:361–367.14. Kim DH, Kim SM, Hyun JK et al. Changes in postoperative recurrence and prognosticrisk factors for patients with gastric cancer who underwent curative gastric resectionduring different time periods. AnnSurgOncol 2013; 20:2317 –2327.15. Japanese Gastric Cancer Association. Japanese Classification of GastricCarcinoma,13 ed. Tokyo:Kandera 1999.16. Akazawa K, Nakamura T, Palesch Y. Power of logrank test and Cox regression modelinclinical trialswith heterogeneoussamples.StatMed1997; 16: 583 –597.17. Harrell FE, Jr, Califf RM, Pryor DB et al. Evaluating theyield of medical tests. JAMA1982;247: 2543–2546.18. Akaike H. Information Theory and an Extension of the Maximum LikelihoodPrinciple.Budapest: Hungary AkademiaiKiado 1973.19. NakajimaT, Kinoshita T, Nashimoto A et al. Randomized controlled trial of adjuvanturacil-tegafur versus surgery alone for serosa-negative, locally advanced gastriccancer.Br JSurg 2007; 94: 1468–1476.20. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy forgastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357:1810–1820.21. Bang YJ, Kim YW, Yang HK et al. Adjuvant capecitabine and oxaliplatin for gastriccancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomisedcontrolled trial. Lancet 2012; 379:315–321.